ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

LTRN Lantern Pharma Inc

5.23
-0.23 (-4.21%)
2024年4月27日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Lantern Pharma Inc LTRN NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.23 -4.21% 5.23 06:38:25
始値 安値 高値 終値 前日終値
5.55 5.42 6.04 5.50 5.46
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/2421:00BWLantern Pharma Launches “Webinar Wednesdays” Featuring..
2024/4/2221:12BWLantern Pharma Receives Regulatory Approval to Expand..
2024/3/1905:02BWLantern Pharma Reports Fourth Quarter & Fiscal Year 2023..
2024/3/1820:12IHMARKETNEWSAnticipation Builds on Wall Street for Federal Reserve’s..
2024/3/1521:00BWLantern Pharma Announces Initial Patients Dosed in..
2024/3/1120:30BWLantern Pharma to Report Fourth Quarter and Fiscal Year 2023..
2024/3/0522:01BWLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st..
2024/3/0422:01BWLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion..
2024/3/0111:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1522:01BWLantern Pharma Advances Unique ADC (Antibody Drug Conjugate)..
2024/1/2006:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1721:30BWStarlight Therapeutics, a Subsidiary of Lantern Pharma..
2023/12/3006:05EDGAR2Form 8-K - Current report
2023/12/0120:02EDGAR2Form SC 13D/A - General statement of acquisition of..
2023/12/0120:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/3022:00BWFDA Grants Lantern Pharma Orphan Drug Designation for Drug..
2023/11/2506:05EDGAR2Form 8-K - Current report
2023/11/0906:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0906:05EDGAR2Form 8-K - Current report
2023/11/0906:01BWLantern Pharma Reports Third Quarter 2023 Financial Results..
2023/11/0121:00BWLantern Pharma to Report Third Quarter 2023 Operating &..
2023/10/2106:25EDGAR2Form 8-K - Current report
2023/10/1021:00BWLantern Pharma to Present at the ThinkEquity Conference on..
2023/10/0321:00BWLantern Pharma Announces Publication in Clinical Cancer..
2023/9/2521:30BWLantern Pharma Announces First Patient Dosed in the Phase 1..
2023/9/1822:00BWLantern Pharma Receives IND Clearance from FDA Enabling..
2023/8/3121:00BWLantern Pharma to Present Data Highlighting the Anti-Tumor..
2023/8/2821:00BWLantern Pharma Expands AI Capabilities of RADR® Platform to..
2023/8/1421:30BWLantern Pharma Receives Notice of US Patent Allowance for..
2023/8/1005:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/1005:05EDGAR2Form 8-K - Current report
2023/8/1005:01BWLantern Pharma Reports Second Quarter 2023 Financial Results..
2023/8/0221:00BWLantern Pharma to Report Second Quarter 2023 Operating &..
2023/7/1721:00BWLantern Pharma to Participate and Present at Multiple..
2023/6/2621:30BWOncotarget Publishes New Data by Lantern Pharma, an AI..
2023/6/1221:30BWLantern Pharma Receives FDA Clearance of IND Application for..
2023/6/0822:00BWLantern Pharma Leverages AI Platform, RADR®, to Develop..
2023/5/1721:00BWLantern Pharma to Present at the Lytham Partners Spring 2023..
2023/5/1005:01BWLantern Pharma Reports First Quarter 2023 Financial Results..
2023/5/0322:00PRNUSLantern Pharma Selects REPROCELL USA to Provide Support for..
2023/5/0305:01BWLantern Pharma to Report First Quarter 2023 Operating &..
2023/5/0220:30BWLantern Pharma Develops Top-Ranked AI Algorithms to Predict..

最近閲覧した銘柄

Delayed Upgrade Clock